The latest report by IMARC Group, titled “Poultry Vaccines Market Size, Share, Trends and Forecast by Disease, Product, Dosage Form, Application, End User, and Region, 2026-2034,” finds that the ้ซๆธ ไฝ่ฒ็ดๆญ:global poultry vaccines market size reached USD 2.1 Billion in 2025. Poultry vaccines help prevent any disease that infects the immune system of bird species, including duck, chicken, turkey, and goose. They produce antibodies that fight against organisms, such as Salmonella, E. Coli, and Mycoplasma gallisepticum (MG), and diseases such as Marek’s disease, infectious bronchitis (IB), avia๐n rhinotracheitis (ART), Newcastle disease and infectious bursal disease (Gumboro disease). Poultry vaccines vary from mild to severe in their dosage, which is approved, only if they pass the World Organization for Animal Health standards. They are administered via various routes such as nasal, oral, subcutaneous ocular and in-vivo intramuscular. Poultry vaccines are applied to different areas of the egg, such as the body of the embryo, allantois sac, yolk sac, and amniotic fluid.
Global Poultry Vaccines Market Trends:
The market is primarily driven by the rising awareness regarding animal vaccination among veterinary practitioners and increasing prevalence of zoonotic diseases. Diseases, such as bird flu or avian influenza, are also known to infect humans and animals. Besides this, the escalating demand for animal health diagnostics also represents a major factor contributing to the market growth. In addition, the growing consumption of meat and poultry-related food products is facilitating extensive expenditure on poultry healthcare. Along with this, governmental bodies across the globe are taking initiatives to educate people regarding the benefits of poultry vaccines, thus accelerating the product adoption rate. Furthermore, growing research and development (R&D) activities to develop advanced technologies to manufacture effective vaccines are creating a positive outlook for the market. For instance, there has been an introduction of live, non-replicating recombinant antigens, nucleic acid-mediated, and live-gene detected vaccines. On account of these factors, the market value is expected to reach USD 3.4 Billion by 2034, exhibiting a CAGR of 5.10% during the forecast period (2026-2034).Market Summary:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2034 |
| Units | Billion USD |
| Segment Coverage | Disease, Product, Dosage Form, Application, End User, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered | AniCon Labor GmbH (SAN Group), Biovac Ltd., Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco, Hester Biosciences Limited, Merck & Co. Inc., Phibro Animal Health Corporation, Venkys India and Zoetis Inc. |
| Customization Scope | 10% Free Customization |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91๐ธ-120-433-0800